Date: 26 November 2013
Aspergillus terreus Thom. Conidial head of Aspergillus terreus. Conidial heads are compact, columnar and biseriate. Conidiophores are hyaline to slightly yellow and smooth walled.
Copyright:
With thanks to G Kaminski. D Ellis and R Hermanis Mycology Unit, Women’s & Children’s Hospital , Adelaide, South Australia 5006
Notes:
Colonies on CYA 40-50 mm diam, plane, low and velutinous, usually quite dense; mycelium white; conidial production heavy, brown (Dark Blonde to Camel, 5-6D4); reverse pale to dull brown or yellow brown. Colonies on MEA 40-60 mm diam, similar to those on CYA or less dense. Colonies on G25N 18-22 mm diam, plane or irregularly wrinkled, low and sparse; conidial production light, pale brown; brown soluble pigment sometimes produced; reverse brown. No growth at 5°C. Colonies at 37°C growing very rapidly, 50 mm or more diam, of similar appearance to those on CYA at 25°C.Conidiophores borne from surface hyphae, stipes 100-250 μm long, smooth walled; vesicles 15-20 μm diam, fertile over the upper hemisphere, with densely packed, short, narrow metulae and phialides, both 5-8 μm long; conidia spherical, very small, 1.8-2.5 μm diam, smooth walled, at maturity borne in long, well defined columns.Distinctive featuresVelutinous colonies formed at both 25°C and 37°C, uniformly brown, with no other colouration, and minute conidia borne in long columns make Aspergillus terreus a distinctive species.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
